Statistics

 array:23 [
  "pii" => "S0365059622001386"
  "issn" => "03650596"
  "doi" => "10.1016/j.abd.2022.03.003"
  "estado" => "S300"
  "fechaPublicacion" => "2022-09-01"
  "aid" => "600"
  "copyrightAnyo" => "2022"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by/4.0/"
  "subdocumento" => "fla"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "pt" => array:18 [
      "pii" => "S2666275222001849"
      "issn" => "26662752"
      "doi" => "10.1016/j.abdp.2022.07.027"
      "estado" => "S300"
      "fechaPublicacion" => "2022-09-01"
      "aid" => "600"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by/4.0/"
      "subdocumento" => "fla"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "pt" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Artigo original</span>"
        "titulo" => "Omalizumabe <span class="elsevierStyleItalic">versus</span> ciclosporina&#8208;A para o tratamento da urtic&#225;ria cr&#244;nica espont&#226;nea&#58; podemos definir end&#243;tipos com melhor resposta&#63;"
        "tienePdf" => "pt"
        "tieneTextoCompleto" => "pt"
        "tieneResumen" => "pt"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "592"
            "paginaFinal" => "600"
          ]
        ]
        "contieneResumen" => array:1 [
          "pt" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "pt" => true
        ]
        "contienePdf" => array:1 [
          "pt" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figura 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 1672
                "Ancho" => 1675
                "Tamanyo" => 197262
              ]
            ]
            "descripcion" => array:1 [
              "pt" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Distribui&#231;&#227;o dos quatro tipos de respostas ao tratamento da UCE&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Emek Kocat&#252;rk, Emel B&#252;lb&#252;l Ba&#351;kan, &#214;zlem Su K&#252;&#231;&#252;k, Mustafa &#214;zdemir, Sinem &#214;rnek, Pelin Kuteyla Can, Eda Ha&#351;al, Burhan Engin, Nilg&#252;n Atakan, Erkan Alpsoy"
            "autores" => array:10 [
              0 => array:2 [
                "nombre" => "Emek"
                "apellidos" => "Kocat&#252;rk"
              ]
              1 => array:2 [
                "nombre" => "Emel B&#252;lb&#252;l"
                "apellidos" => "Ba&#351;kan"
              ]
              2 => array:2 [
                "nombre" => "&#214;zlem Su"
                "apellidos" => "K&#252;&#231;&#252;k"
              ]
              3 => array:2 [
                "nombre" => "Mustafa"
                "apellidos" => "&#214;zdemir"
              ]
              4 => array:2 [
                "nombre" => "Sinem"
                "apellidos" => "&#214;rnek"
              ]
              5 => array:2 [
                "nombre" => "Pelin Kuteyla"
                "apellidos" => "Can"
              ]
              6 => array:2 [
                "nombre" => "Eda"
                "apellidos" => "Ha&#351;al"
              ]
              7 => array:2 [
                "nombre" => "Burhan"
                "apellidos" => "Engin"
              ]
              8 => array:2 [
                "nombre" => "Nilg&#252;n"
                "apellidos" => "Atakan"
              ]
              9 => array:2 [
                "nombre" => "Erkan"
                "apellidos" => "Alpsoy"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "pt"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S0365059622001386"
          "doi" => "10.1016/j.abd.2022.03.003"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059622001386?idApp=UINPBA00008Z"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222001849?idApp=UINPBA00008Z"
      "url" => "/26662752/0000009700000005/v1_202209080628/S2666275222001849/v1_202209080628/pt/main.assets"
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S036505962200112X"
    "issn" => "03650596"
    "doi" => "10.1016/j.abd.2021.12.002"
    "estado" => "S300"
    "fechaPublicacion" => "2022-09-01"
    "aid" => "574"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by/4.0/"
    "subdocumento" => "fla"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "Predictive factors of melanoma thickness"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "601"
          "paginaFinal" => "605"
        ]
      ]
      "contieneResumen" => array:1 [
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ana Rita Carreiro Silva, Ricardo Jos&#233; David Costa Vieira"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "Ana Rita Carreiro"
              "apellidos" => "Silva"
            ]
            1 => array:2 [
              "nombre" => "Ricardo Jos&#233; David Costa"
              "apellidos" => "Vieira"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "pt" => array:9 [
        "pii" => "S2666275222001412"
        "doi" => "10.1016/j.abdp.2022.07.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "pt"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222001412?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S036505962200112X?idApp=UINPBA00008Z"
    "url" => "/03650596/0000009700000005/v1_202208290604/S036505962200112X/v1_202208290604/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S0365059622001283"
    "issn" => "03650596"
    "doi" => "10.1016/j.abd.2021.09.013"
    "estado" => "S300"
    "fechaPublicacion" => "2022-09-01"
    "aid" => "590"
    "copyright" => "Sociedade Brasileira de Dermatologia"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by/4.0/"
    "subdocumento" => "fla"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "Intraoperative assessment of surgical margins using &#8220;<span class="elsevierStyleItalic">en face</span>&#8221; frozen sections in the management of cutaneous carcinomas"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "583"
          "paginaFinal" => "591"
        ]
      ]
      "contieneResumen" => array:1 [
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0010"
          "etiqueta" => "Figure 2"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr2.jpeg"
              "Alto" => 1775
              "Ancho" => 2925
              "Tamanyo" => 324044
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0010"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41;&#44; The peripheral and deep margins of the specimen are painted by the pathologist&#46; &#40;B&#41;&#44; Excision of the peripheral margin of the specimen&#44; to be sent for the preparation of the frozen sections&#44; consists of a 2&#46;0 to 3&#46;0 mm thick specimen obtained at the reference point with an incision parallel to the peripheral margin&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ana Carolina Vasconcellos Guedes Otsuka, Eduardo Bertolli, Mariana Petaccia de Macedo, Clovis Antonio Lopes Pinto, Jo&#227;o Pedreira Duprat Neto"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Ana Carolina Vasconcellos Guedes"
              "apellidos" => "Otsuka"
            ]
            1 => array:2 [
              "nombre" => "Eduardo"
              "apellidos" => "Bertolli"
            ]
            2 => array:2 [
              "nombre" => "Mariana Petaccia"
              "apellidos" => "de Macedo"
            ]
            3 => array:2 [
              "nombre" => "Clovis Antonio Lopes"
              "apellidos" => "Pinto"
            ]
            4 => array:2 [
              "nombre" => "Jo&#227;o Pedreira"
              "apellidos" => "Duprat Neto"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "pt" => array:9 [
        "pii" => "S2666275222001552"
        "doi" => "10.1016/j.abdp.2022.07.017"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "pt"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222001552?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059622001283?idApp=UINPBA00008Z"
    "url" => "/03650596/0000009700000005/v1_202208290604/S0365059622001283/v1_202208290604/en/main.assets"
  ]
  "en" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
    "titulo" => "Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria&#58; can we define better-responding endotypes&#63;"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "592"
        "paginaFinal" => "600"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Emek Kocat&#252;rk, Emel B&#252;lb&#252;l Ba&#351;kan, &#214;zlem Su K&#252;&#231;&#252;k, Mustafa &#214;zdemir, Sinem &#214;rnek, Pelin Kuteyla Can, Eda Ha&#351;al, Burhan Engin, Nilg&#252;n Atakan, Erkan Alpsoy"
        "autores" => array:10 [
          0 => array:4 [
            "nombre" => "Emek"
            "apellidos" => "Kocat&#252;rk"
            "email" => array:1 [
              0 => "ekocaturk@ku.edu.tr"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Emel B&#252;lb&#252;l"
            "apellidos" => "Ba&#351;kan"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "&#214;zlem Su"
            "apellidos" => "K&#252;&#231;&#252;k"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Mustafa"
            "apellidos" => "&#214;zdemir"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Sinem"
            "apellidos" => "&#214;rnek"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Pelin Kuteyla"
            "apellidos" => "Can"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Eda"
            "apellidos" => "Ha&#351;al"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Burhan"
            "apellidos" => "Engin"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Nilg&#252;n"
            "apellidos" => "Atakan"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Erkan"
            "apellidos" => "Alpsoy"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:9 [
          0 => array:3 [
            "entidad" => "Department of Dermatology&#44; Koc University&#44; School of Medicine&#44; Istanbul&#44; Turkey"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Department of Dermatology&#44; Uludag University&#44; School of Medicine&#44; Bursa&#44; Turkey"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Department of Dermatology&#44; Bezmialem Vakif University&#44; School of Medicine&#44; Istanbul&#44; Turkey"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Department of Dermatology&#44; Istanbul Medipol University&#44; School of Medicine&#44; Istanbul&#44; Turkey"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Department of Dermatology&#44; Ankara Diskapi Yildirim Beyazit Training and Research Hospital&#44; Ankara&#44; Turkey"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Department of Dermatology&#44; VM Medical Park Maltepe Hospital&#44; Istanbul&#44; Turkey"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Department of Dermatology&#44; Istanbul University&#44; Cerrahpasa School of Medicine&#44; Istanbul&#44; Turkey"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Department of Dermatology&#44; Hacettepe University&#44; School of Medicine&#44; Ankara&#44; Turkey"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Department of Dermatology&#44; Akdeniz University&#44; School of Medicine&#44; Antalya&#44; Turkey"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1672
            "Ancho" => 1675
            "Tamanyo" => 199167
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The distribution of four types of treatment responses&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Chronic Spontaneous Urticaria &#40;CSU&#41; is defined as having wheals and or angioedema for longer than 6 weeks&#46; The main effector cell in the pathophysiology of the disease is the mast cell&#44; which degranulates after stimulation mainly via the high-affinity Fc&#949;R1 and leads to the release of a variety of mediators and results in the recruitment of cells such as basophils&#44; eosinophils and T-lymphocytes&#46;<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1&#44;2</span></a> It is widely accepted that autoimmune mechanisms play a major role in the activation of mast cells&#46; In CSU&#44; two types of autoimmunity are postulated&#59; these are&#58; 1&#41; Type I autoimmunity &#40;also called autoallergy&#41; in which IgE autoantibodies and 2&#41; Type IIb autoimmunity in which IgG autoantibodies against autoantigens activate mast cell receptors&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> The International Urticaria Guidelines recommend Omalizumab &#40;Oma&#41; as the first-line treatment in antihistamine resistant &#40;patients who do not respond to four-fold doses of H1-antihistamines&#41; CSU and Cyclosporine-A &#40;Cs-A&#41; is recommended in patients who fail on Omalizumab &#40;Oma&#41; treatment&#46; Although this step-wise algorithm has been adopted&#44; it might be time-consuming&#44; costly&#44; and might not be suitable for all CSU patients&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> There have been attempts to find biomarkers or clinical features which define response to treatment in CSU patients and&#59; autologous serum test&#44; basophil histamine release assay &#40;BHRA&#41;&#44; total IgE levels&#44; d-dimer and CRP are some of the biomarkers that have been found to be associated with response to Oma or Cs-A treatment&#46;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> However&#44; many of the studies that have been performed to determine biomarkers focused on a certain drug which in this case is Oma or Cs-A&#44; but there is a lack of studies that compare Oma-responders with Cs-A-responders&#46; In this study&#44; we aimed to determine if specific patient characteristics or laboratory markers could be used as indicators of Oma or Cs-A response in CSU patients&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Methods</span><p id="par0010" class="elsevierStylePara elsevierViewall">We retrospectively analyzed patient files from 7 centers in Turkey &#40;Okmeydani Training and Research Hospital&#44; Istanbul&#59; Uludag University&#44; School of Medicine&#44; Bursa&#59; Bezmialem Vakif University&#44; School of Medicine&#44; Istanbul&#59; Istanbul Medipol University&#44; School of Medicine&#44; Istanbul&#59; Istanbul University&#44; Cerrahpasa School of Medicine&#44; Istanbul&#59; Hacettepe University&#44; School of Medicine&#44; Ankara&#59; Akdeniz University&#44; School of Medicine&#44; Antalya&#41; that are experienced in treating CSU patients&#46; The diagnosis of CSU was made based on physical examination and patient history&#46; Patients were considered antihistamine resistant when they did not respond to four-fold doses of H1-antihistamines&#46; The inclusion criteria for CSU patients were to&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1</span><p id="par0015" class="elsevierStylePara elsevierViewall">Have chronic spontaneous urticaria for longer than 6-weeks&#44;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">2</span><p id="par0020" class="elsevierStylePara elsevierViewall">To be aged over 18-years&#44;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">3</span><p id="par0025" class="elsevierStylePara elsevierViewall">Not to be pregnant and breastfeeding&#44;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">4</span><p id="par0030" class="elsevierStylePara elsevierViewall">To receive a trial of both Oma and Cs-A treatment &#40;not concurrently&#41; during their disease course for at least 3-months to decide if there is a response to treatment or not&#44;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">5</span><p id="par0035" class="elsevierStylePara elsevierViewall">To include Urticaria Control Test &#40;UCT&#41; scores and sufficient clinical and laboratory data in the files&#46;</p></li></ul></p><p id="par0040" class="elsevierStylePara elsevierViewall">Exclusion criteria were to&#58;<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">1</span><p id="par0045" class="elsevierStylePara elsevierViewall">Chronic inducible urticaria&#44;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">2</span><p id="par0050" class="elsevierStylePara elsevierViewall">Patients under 18 years of age&#44;</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">3</span><p id="par0055" class="elsevierStylePara elsevierViewall">Take both Cs-A and Oma at the same time&#46;</p></li></ul></p><p id="par0060" class="elsevierStylePara elsevierViewall">Response to treatment was defined by UCT scores &#40;UCT &#8805; 12&#59; under control&#41;&#46; Four groups of patients were defined according to treatment responses&#58;<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">1</span><p id="par0065" class="elsevierStylePara elsevierViewall">Patients who respond to only Oma &#40;do not respond to CsA&#41; &#40;Oma-resp<span class="elsevierStyleSup">&#43;</span>&#41;&#44;</p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">2</span><p id="par0070" class="elsevierStylePara elsevierViewall">Patients who respond to only Cs-A &#40;do not respond to Oma&#41; &#40;Cs-A-resp<span class="elsevierStyleSup">&#43;</span>&#41;&#44;</p></li><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">3</span><p id="par0075" class="elsevierStylePara elsevierViewall">Patients who respond to both Oma and Cs-A &#40;Oma-Cs-A-resp<span class="elsevierStyleSup">&#43;</span>&#41;&#44;</p></li><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">4</span><p id="par0080" class="elsevierStylePara elsevierViewall">Patients who do not respond to either drug &#40;Oma-Cs-A-resp<span class="elsevierStyleSup">-</span>&#41;&#46;</p></li></ul></p><p id="par0085" class="elsevierStylePara elsevierViewall">We performed a comparison among all response groups in terms of features such as age&#44; gender&#44; family history&#44; presence of angioedema&#44; disease duration&#44; accompanying inducible Urticaria &#40;CIndU&#41;&#44; baseline UCT scores and laboratory markers such as Autologous Serum Skin Test &#40;ASST&#41;&#44; high CRP&#44; high ESR&#44; eosinopenia&#44; basopenia&#44; low total IgE levels&#44; presence of autoimmune thyroid disease as well as anti-Thyroid Peroxidase &#40;anti-TPO&#41; and anti-Thyroglobuline &#40;anti-TG&#41; positivity&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">Ethics approval was taken from the coordinating center Okmeydani Training and Research Hospital&#8217;s Ethics Committee &#40;date 23&#46;05&#46;2017&#59; issue 98-667&#41;&#46;</p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Definitions</span><p id="par0095" class="elsevierStylePara elsevierViewall">High levels of CRP&#58; &#8805;5 mg&#47;L&#44;</p><p id="par0100" class="elsevierStylePara elsevierViewall">High levels of ESR&#58; &#8805;20 mm&#47;h&#44;</p><p id="par0105" class="elsevierStylePara elsevierViewall">Basopenia &#60;0&#46;01 &#215; 10<span class="elsevierStyleSup">9</span>&#47;L&#44;</p><p id="par0110" class="elsevierStylePara elsevierViewall">Eosinopenia &#60;0&#46;05 &#215; 10<span class="elsevierStyleSup">9</span>&#47;L&#44;</p><p id="par0115" class="elsevierStylePara elsevierViewall">Low total IgE levels &#60;43 IU&#47;mL&#44;</p><p id="par0120" class="elsevierStylePara elsevierViewall">Autoimmune Thyroid disease &#40;AIT&#41;&#58; established diagnosis of AIT found in patient charts &#40;not from only anti-Thyroid Peroxidase &#40;TPO&#41; &#47;anti-Thyroglobuline &#40;TG&#41; positivity&#41;&#44;</p><p id="par0125" class="elsevierStylePara elsevierViewall">High disease activity UCT &#60; 6&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Statistical analysis</span><p id="par0130" class="elsevierStylePara elsevierViewall">We described baseline characteristics with means and Standard Deviations &#40;SD&#41; for continuous variables and frequencies and percentages for categorical variables&#46; Pearson&#8217;s Chi-Squared and Fisher&#39;s exact test were used for group comparison of categorical variables&#46; Mann-Whitney <span class="elsevierStyleItalic">U</span> test was used for the comparisons of continuous variables between groups&#46; Only low IgE could be claimed to have an association with Cs-A treatment outcomes<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> that would confound the associations presented in previous papers though it is not fully confirmed&#46; We&#44; therefore&#44; used multinominal logistic regression models to calculate low IgE &#40;lower than 43&#41;-adjusted ORs &#40;aAORs&#41; to examine associations between Cs-A treatment outcomes for CSU&#59; p-values lower than 0&#46;05&#44; two-sided&#44; were considered statistically significant&#46;</p></span></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Results</span><p id="par0135" class="elsevierStylePara elsevierViewall">One-hundred-ten CSU patient files were included from 7 centers &#40;74 female &#91;67&#46;3&#37;&#93;&#44; mean age 40&#46;98 &#177; 12&#46;37&#59; range&#58; 16-81 years&#44; mean disease duration 57&#46;21 &#177; 69&#46;31&#59; range&#58; 6&#8210;402 months&#41;&#46; The demographic characteristics of the patients are presented in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#46; Four types of treatment responses were distributed as follows&#58; 47 &#40;42&#46;7&#37;&#41; Oma-resp<span class="elsevierStyleSup">&#43;</span>&#44; 15 &#40;13&#46;6&#37;&#41; Cs-A-resp&#43;&#44; 24 &#40;21&#46;8&#37;&#41; Oma-Cs-A-resp &#43; and 24 &#40;21&#46;8&#37;&#41; Oma-Cs-A-resp- &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; The laboratory findings of the patients are presented in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#46; Statistically significant differences&#44; as well as statistically not significant but more frequent features&#44; are presented in <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">No significant differences between Oma-responders and Cs-A-responders but some features are more prevalent in Cs-A-responders</span><p id="par0140" class="elsevierStylePara elsevierViewall">When a comparison was performed between patients who responded only to Oma &#40;n &#61; 47&#41; and only to Cs-A &#40;n &#61; 15&#41;&#44; there were no statistically significant differences between the groups in terms of the clinical and laboratory parameters&#46; But positive ASST &#40;52&#46;8&#37; vs&#46; 71&#46;4&#37;&#59; p &#61; 0&#46;47&#41;&#44; positive family history &#40;4&#46;3&#37; vs&#46; 20&#37;&#59; p &#61; 0&#46;086&#41;&#44; high levels of CRP &#40;42&#46;1&#37; vs&#46; 72&#46;7&#37;&#59; p &#61; 0&#46;074&#41;&#44; basopenia &#40;2&#46;2&#37; vs&#46; 16&#46;7&#37;&#59; p &#61; 0&#46;10&#41;&#44; eosinopenia &#40;0 vs&#46; 20&#37;&#59; p &#61; 0&#46;08&#41;&#44; high levels of ESR &#40;34&#46;1&#37; vs&#46; 61&#46;5&#37;&#59; p &#61; 0&#46;07&#41;&#44; low total IgE levels &#40;20&#46;9&#37; vs&#46; 41&#46;7&#37;&#59; p &#61; 0&#46;259&#41;&#44; anti-TPO positivity &#40;37&#46;9&#37; vs&#46; 50&#37;&#59; p &#61; 0&#46;69&#41; and lower baseline UCT scores &#40;6 vs&#46; 3&#59; p &#61; 0&#46;122&#41; were more frequent in Cs-A-resp<span class="elsevierStyleSup">&#43;</span> even though these were not statistically significant&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Oma-responders have higher baseline UCT scores compared to Oma-non-responders</span><p id="par0145" class="elsevierStylePara elsevierViewall">When Oma-resp<span class="elsevierStyleSup">&#43;</span> &#40;n &#61; 47&#41; were compared to Oma-resp<span class="elsevierStyleSup">-</span> &#40;Oma-Cs-A-resp<span class="elsevierStyleSup">-</span> and Cs-A-resp<span class="elsevierStyleSup">&#43;</span>&#59; n &#61; 39&#41;&#44; the only statistically significant parameter was baseline UCT score which was 6 vs&#46; 4&#46;5 in Oma-resp<span class="elsevierStyleSup">&#43;</span> vs&#46; Cs-A-resp<span class="elsevierStyleSup">&#43;</span> and Oma-Cs-A-resp<span class="elsevierStyleSup">-</span>&#44; respectively &#40;p &#61; 0&#46;045&#41;&#46; Other features which were observed without statistical significance in Oma-resp<span class="elsevierStyleSup">&#43;</span> were higher rate male gender &#40;38&#46;3&#37; vs&#46; 23&#46;1&#37;&#59; p &#61; 0&#46;13&#41;&#44; lower ratio of ASST positivity &#40;52&#46;8&#37; vs&#46; 62&#46;5&#37;&#59; p &#61; 0&#46;45&#41;&#44; lower ratio of family history &#40;4&#46;3&#37; vs&#46; 15&#46;4&#37;&#59; p &#61; 0&#46;13&#41;&#44; lower frequency of high CRP &#40;42&#46;1&#37; vs&#46; 55&#46;2&#37;&#59; p &#61; 0&#46;29&#41;&#44; lower frequency of eosinopenia &#40;0&#37; vs&#46; 13&#46;6&#37;&#59; p &#61; 0&#46;10&#41;&#44; lower frequency of basopenia &#40;2&#46;2&#37; vs&#46; 9&#46;4&#37;&#59; p &#61; 0&#46;30&#41;&#44; lower frequency of high ESR levels &#40;34&#46;1&#37; vs&#46; 44&#46;1&#37;&#59; p &#61; 0&#46;36&#41;&#44; lower frequency of angioedema &#40;57&#46;4&#37; vs&#46; 69&#46;2&#37;&#59; p &#61; 0&#46;26&#41;&#44; lower frequency of autoimmune thyroid disease &#40;22&#46;9&#37; vs&#46; 26&#46;9&#37;&#59; p &#61; 0&#46;71&#41; and higher frequency of total IgE levels greater than 43 &#40;79&#46;1&#37; vs&#46; 66&#46;7&#37;&#59; p &#61; 0&#46;22&#41;&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">High CRP levels are more frequent in Cs-A-responders compared to Cs-A-non-responders</span><p id="par0150" class="elsevierStylePara elsevierViewall">The only statistically significant difference between Cs-A-resp<span class="elsevierStyleSup">&#43;</span> &#40;n &#61; 15&#41; and Cs-A-resp- &#40;Oma-Cs-A-resp<span class="elsevierStyleSup">-</span>&#44; Oma-resp<span class="elsevierStyleSup">&#43;</span> and Oma-Cs-A-resp<span class="elsevierStyleSup">&#43;</span>&#59; n &#61; 95&#41; was high levels of CRP which was more frequent among Cs-A-resp<span class="elsevierStyleSup">&#43;</span> &#40;72&#46;7&#37; vs&#46; 40&#46;3&#37;&#59; OR &#61; 3&#46;96&#44; 95&#37; CI 0&#46;97&#8210;16&#46;1&#59; p &#61; 0&#46;05&#41; and having high CRP levels increased the chance of favorable treatment response to Cs-A by 6&#46;1 after adjusting for low levels of total IgE &#40;aOR &#61; 6&#46;1&#59; 95&#37; CI 1&#46;17&#8210;31&#46;8&#59; p &#61; 0&#46;032&#41;&#46;</p><p id="par0155" class="elsevierStylePara elsevierViewall">Positive family history &#40;20&#37; vs&#46; 8&#46;4&#37;&#59; p &#61; 0&#46;172&#41;&#44; positive ASST &#40;71&#46;4&#37; vs&#46; 55&#46;7&#37;&#59; p &#61; 0&#46;692&#41;&#44; eosinopenia &#40;20&#37; vs&#46; 2&#46;3&#37;&#59; p &#61; 0&#46;085&#41;&#44; basopenia &#40;16&#46;7&#37; vs&#46; 2&#46;2&#37;&#59; p &#61; 0&#46;067&#41;&#44; high ESR levels &#40;61&#46;5&#37; vs&#46; 36&#37;&#59; p &#61; 0&#46;08&#41;&#44; lower total IgE levels &#40;41&#46;7&#37; vs&#46; 22&#37;&#59; p &#61; 0&#46;159&#41;&#44; anti-TPO positivity &#40;50&#37; vs 32&#46;8&#37;&#59; p &#61; 0&#46;436&#41;&#44; lower baseline UCT scores &#40;3 vs&#46; 7&#59; p &#61; 0&#46;107&#41; were more frequent without statistical significance in Cs-A-resp<span class="elsevierStyleSup">&#43;</span>&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Female gender and lower baseline UCT were more frequent in non-responders of either drug</span><p id="par0160" class="elsevierStylePara elsevierViewall">Non-responders of either drug was compared to all responder groups &#40;Oma-resp<span class="elsevierStyleSup">&#43;</span>&#44; Cs-A-resp<span class="elsevierStyleSup">&#43;</span> and Oma-Cs-A-resp<span class="elsevierStyleSup">&#43;</span>&#41; and the comparison revealed that the majority of Oma-Cs-A-resp<span class="elsevierStyleSup">-</span> were females &#40;21&#59;87&#46;5&#37; vs&#46; 53&#59;61&#46;6&#37;&#59; p &#61; 0&#46;017&#41; and baseline UCT was lower in Oma-Cs-A-resp- &#40;5 vs&#46; 7&#59; p &#61; 0&#46;06&#41;&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Responders to both drugs had less angioedema and higher baseline UCT</span><p id="par0165" class="elsevierStylePara elsevierViewall">Oma-Cs-A-resp<span class="elsevierStyleSup">&#43;</span> were compared to the rest of the patients &#40;Oma-resp<span class="elsevierStyleSup">&#43;</span>&#44; Cs-A-resp<span class="elsevierStyleSup">&#43;</span> and Oma-Cs-A-resp<span class="elsevierStyleSup">-</span>&#41;&#46; Angioedema frequency was lower &#40;8&#59;33&#46;3&#37; vs&#46; 54&#59;62&#46;8&#37;&#59; p &#61; 0&#46;01&#41; and baseline UCT was higher in Oma-Cs-A-resp<span class="elsevierStyleSup">&#43;</span> &#40;8 vs&#46; 5&#59; p &#61; 0&#46;017&#41;&#46;</p></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Discussion</span><p id="par0170" class="elsevierStylePara elsevierViewall">In this study&#44; we found that in a subpopulation of antihistamine refractory CSU patients who received both Oma and Cs-A any time during their follow up&#44; the majority &#40;forty percent&#41; responded to Oma&#44; the minority &#40;ten percent&#41; responded to Cs-A&#44; while twenty percent responded to both Oma and Cs-A and another twenty percent did not respond to either drug &#40;Summary of findings in <a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>&#41;&#46; These findings are interesting owing to the reports of high response rates of CSU patients to Cs-A treatment which ranged between 38&#37; to 100&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> We would have expected more patients to be responding to Cs-A treatment however after careful examination of clinical and laboratory findings of the studied patient population&#44; t 65&#37; of our patient population had high total IgE levels &#40;higher than 100 IU&#47;mL&#41; which have been reported to be a feature of type I autoimmune CSU and an unfavorable factor for Cs-A response&#46;<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3&#44;5</span></a> Maurer et al&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> described some features of type I versus type IIb autoimmune CSU and pointed out that the presence of auto-IgE &#40;eg&#59; against TPO&#44; IL-24&#44; ds-DNA&#41;&#44; higher rates of concomitant allergic diseases&#44; normal or high total IgE levels and high response rate to oma favors type I autoimmune CSU while the presence of auto-IgG &#40;against IgE&#44; Fc&#949;RI&#41;&#44; higher disease activity&#44; longer disease duration&#44; higher rates of concomitant autoimmune diseases&#44; lower total IgE levels&#44; higher rates of eosinopenia and basopenia&#44; higher levels of CRP&#44; higher rates of ANA positivity&#44; low response rate or slower response to Oma and good response to immunosuppressive treatment&#46; Based on this endotype classification&#44; we can explain why the response rate to Cs-A is low in the studied patient population&#59; we believe the low frequency of patients with eosinopenia&#44; basopenia&#44; low IgE levels&#44; high CRP levels&#44; and high disease severity&#59; but high frequency of patients with high total IgE levels show that the majority of the patient population are composed of type I autoimmune CSU and therefore more prone to respond to Oma treatment&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0175" class="elsevierStylePara elsevierViewall">Searching for biomarkers that predict response to a particular treatment has been a matter of interest and many publications reported some biomarkers might be helpful in determining response to certain treatments in CSU&#46; For Oma&#44; high levels of IgE&#44; ASST negativity&#44; BHRA negativity&#44; the lack of basophil CD203c-upregulating activity&#44; high expression of basophil Fc&#949;RI and lower IL-31 levels have been reported to be biomarkers for good treatment response&#44; while for cyclosporine&#44; BHRA positivity&#44; higher CRP levels&#44; low IgE levels&#44; ASST positivity&#44; low D-dimer levels&#44; high disease activity&#44; and short disease duration were indicative of good treatment response&#46;<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4&#44;7</span></a> In the present study population&#44; the authors could not find a statistically significant difference between Oma and Cs-A responders with respect to the comparison parameters but this might be the result of the imbalanced distribution of patients with certain parameters&#59; as mentioned before the authors have a lower percentage of patients with good response to Cs-A treatment that could have resulted in a limitation of statistical analysis&#59; that is mainly due to the choice of omalizumab as a first-line treatment in antihistamine refractory patients&#46; Comparison between groups showed positive ASST&#44; positive family history&#44; high levels of CRP&#44; basopenia&#44; eosinopenia&#44; high levels of ESR&#44; low total IgE levels&#44; anti-TPO positivity&#44; and lower baseline UCT scores were more frequent in Cs-A responders than Oma-responders&#46; These findings again refer to the importance of endotypes of CSU&#59; the mentioned parameters associated with cyclosporine response are also features of type IIb autoimmune CSU&#46; Type IIb autoimmune urticaria is defined by IgG anti&#8208;IgE or Fc&#949;RI&#44; a positive Basophil Activation Test &#40;BAT&#41;&#44; and a positive ASST and has been shown to respond better to Cs-A treatment&#46;<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8&#8211;11</span></a> The authors also found that patients with high CRP levels responded better to Cs-A&#44; which is a finding&#44; reported in previous studies&#46;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> Furthermore&#44; the authors observed that low total IgE levels were more frequent in Cs-A responders as was reported by Santiago et al&#46;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> Similar to the findings of Hollander et al&#46;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> who reported that higher initial severity predicted a successful response to treatment with cyclosporine&#44; Cs-A responders in the present study had lower UCT scores&#46; Even though Cs-A responders in the present study had a higher frequency of ASST positivity&#44; the evidence of ASST being a potential predictor of treatment response for Cs-A has not been conclusive&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">Omalizumab responders in the present study population were found to have a significantly higher baseline UCT score than omalizumab non-responders&#44; which pointed out to milder disease activity and was also reported by Salman et al&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> Presence of angioedema&#44;<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> female gender&#44;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> high CRP levels&#44;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> ASST positivity&#44;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> eosinopenia and basopenia <a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> has been reported to be associated with poor response to omalizumab&#46; Higher serum total IgE levels are currently accepted as an established biomarker of omalizumab response<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> even though the authors were not able to show this in a statistically significant manner in the present study&#46;</p><p id="par0185" class="elsevierStylePara elsevierViewall">One out of five patients in the present study showed a response to both drugs and these patients were found to have less angioedema and higher baseline UCT scores &#40;lower baseline disease activity&#41; which are features of lower disease activity&#46; It is anticipated to have a favorable response to treatment in patients with lower disease activity&#44; however&#44; it would be illuminative if the authors could perform testing for both IgE autoantibodies and IgG autoantibodies and determine which type of autoimmunity these patients have&#46; Then the authors would hypothesize that these patients might have both types of autoantibodies and therefore both types of autoimmunity&#46; The idea of the presence of such patients comes from the observations of increasing reports of patients who respond to treatment with Oma and Cs-A together&#46; But the patients in these reports do not seem to respond to treatment with either Oma or Cs-A alone but to treatment with a combined regimen&#59; reflecting patients with high disease activity and possibly with two types of autoimmunity&#46;<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">19&#8211;21</span></a> Two types of autoimmunity existing together have been demonstrated in a recent clinical study by Asero et al&#46;<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> who showed the co-existence of IgE and IgG autoantibodies to high- and low-affinity IgE receptors &#40;Fc&#949;RI and Fc&#949;RII&#41;&#44; tissue factor and thyroglobulin&#44; particularly in late responders to omalizumab&#46;</p><p id="par0190" class="elsevierStylePara elsevierViewall">Twenty percent of the patients in this study did not respond to treatment with either Oma or Cs-A&#46; This refractory patient population included more females and more patients with lower baseline UCT scores&#46; These features have also been linked to refractory disease in previous reports&#59; the female gender has been reported to be a predictor of longer time to remission&#44;<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> anti-histamine resistance&#44;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> and higher frequency of recurrence after omalizumab treatment&#46;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> Lower baseline UCT scores have been associated with a lower response rate to omalizumab and a higher need for omalizumab up dosing&#46;<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a> Despite not being statistically significant&#44; the refractory patients in the present study had a higher rate of <span class="elsevierStyleItalic">H&#46;pylori</span> positivity even though the information on <span class="elsevierStyleItalic">H&#46;pylori</span>eradication rates in these patients is lacking&#46; This emphasizes the importance of evaluating and treating comorbid conditions in CSU patients&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">The only study that is in some ways similar to ours is the one published by S&#225;nchez et al&#46; who reported that out of 88 patients in their study&#59; 26&#47;88 &#40;29&#46;5&#37;&#41; responded to Cs-A&#44; 41&#47;88 &#40;46&#46;5&#37;&#41; responded to Oma&#44; 16&#47;88 &#40;18&#46;2&#37;&#41; responded when Cs-A and Oma were combined and only 5 &#40;5&#46;6&#37;&#41; patients were left without response to treatment&#46;<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> Response rates to omalizumab were similar to the present study and were also similar to the complete response rate reported by the clinical trials and real-life studies of omalizumab&#44; which is around 40&#37;&#8210;50&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a> But the rate of non-responders of both drugs seems to be very much lower than in the present study which might be attributed to our preference for not including patients who used both omalizumab and cyclosporine at the same time&#46; If these refractory patients were treated with both drugs&#44; the rate of non-responders could have been decreased&#46;</p><p id="par0200" class="elsevierStylePara elsevierViewall">Why these patients do not respond to both omalizumab and cyclosporine needs to be explored in larger prospective trials&#44; which assess the profile of patients with detailed laboratory examinations including IgG type and IgE type autoantibodies&#44; BAT&#47;BHR testing as well as other inflammatory mediators both in the skin and peripheral blood&#46; These patients might have a different underlying pathomechanism including involvement of complement components&#44; infiltrates in the skin composed of eosinophils&#44; or T-lymphocytes producing other inflammatory cytokines such as IL-4&#44; IL-5&#44; IL-23&#44; IL-17 or IL-31&#44; or other mechanisms including angiogenesis&#44; coagulation&#44; and vascular dysregulation&#46;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> There are many different ranges of therapeutic options for this refractory group of patients which are under clinical trials or in progress of development including dupilumab&#44; fenebrutinib&#44; benralizumab&#44; and anti-siglec-8&#46;<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2&#44;29</span></a></p><p id="par0205" class="elsevierStylePara elsevierViewall">Limitations of the present study are its retrospective nature&#44; which did not include the same number of patients in the outlined four groups&#44; not including patients who were treated with both Cs-A and Oma&#44; having a low number of patients&#44; having no control group&#44; and the lack of BAT or BHRA testing&#46; The cross-sectional nature of the study led to a study population&#44; which might not be reflective of the general urticaria population&#44; but the multicenter nature of the study might have mitigated this effect&#46;</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Conclusion</span><p id="par0210" class="elsevierStylePara elsevierViewall">Categorizing patients into endotypes could be helpful in predicting treatment responses and could aid in choosing the right treatment option for the particular CSU patient&#46; For the ultimate care of patients&#44; determining disease activity at baseline and paying attention to the laboratory markers such as CRP&#44; total IgE and IgG-anti-TPO as well as clinical markers such as female gender and angioedema might be of special importance&#46;</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Funding sources</span><p id="par0215" class="elsevierStylePara elsevierViewall">None&#46;</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Authors&#39; contributions</span><p id="par0220" class="elsevierStylePara elsevierViewall">Emek Kocaturk&#58; Substantial contributions to the study concept and design&#59; Acquisition&#44; analysis&#44; and interpretation of data&#59; Critical review of the literature&#59; Involvement in drafting the manuscript&#59; writing the manuscript&#59; Final approval of the version of the manuscript&#46;</p><p id="par0225" class="elsevierStylePara elsevierViewall">Emel B&#252;lb&#252;l Ba&#351;kan&#58; Data collection&#44; or analysis and interpretation of data&#59; Critical review of important intellectual content&#59; Final approval of the final version of the manuscript&#46;</p><p id="par0230" class="elsevierStylePara elsevierViewall">&#214;zlem Su K&#252;&#231;&#252;k&#58; Data collection&#44; or analysis and interpretation of data&#59; Critical review of important intellectual content&#59; Final approval of the final version of the manuscript&#46;</p><p id="par0235" class="elsevierStylePara elsevierViewall">Mustafa &#214;zdemir&#58; Data collection&#44; or analysis and interpretation of data&#59; Critical review of important intellectual content&#59; Final approval of the final version of the manuscript&#46;</p><p id="par0240" class="elsevierStylePara elsevierViewall">Sinem &#214;rnek&#58; Data collection&#44; or analysis and interpretation of data&#59; Effective participation in the research guidance&#59; Final approval of the final version of the manuscript&#46;</p><p id="par0245" class="elsevierStylePara elsevierViewall">Pelin Kuteyla Can&#58; Data collection&#44; or analysis and interpretation of data&#59; Effective participation in the research guidance&#59; Final approval of the final version of the manuscript&#46;</p><p id="par0250" class="elsevierStylePara elsevierViewall">Eda Ha&#351;al&#58; Data collection&#44; or analysis and interpretation of data&#59; Effective participation in the research guidance&#59; Final approval of the final version of the manuscript&#46;</p><p id="par0255" class="elsevierStylePara elsevierViewall">Burhan Engin&#58; Data collection&#44; or analysis and interpretation of data&#59; Critical review of important intellectual content&#59; Final approval of the final version of the manuscript&#46;</p><p id="par0260" class="elsevierStylePara elsevierViewall">Nilg&#252;n Atakan&#58; Data collection&#44; or analysis and interpretation of data&#59; Critical review of important intellectual content&#59; Final approval of the final version of the manuscript&#46;</p><p id="par0265" class="elsevierStylePara elsevierViewall">Erkan Alpsoy&#58; Data collection&#44; or analysis and interpretation of data&#59; Critical review of important intellectual content&#59; Final approval of the final version of the manuscript&#46;</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Conflicts of interest</span><p id="par0270" class="elsevierStylePara elsevierViewall">None declared&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:11 [
        0 => array:3 [
          "identificador" => "xres1763865"
          "titulo" => "Abstract"
          "secciones" => array:6 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Background"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Objective"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Methods"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Results"
            ]
            4 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Study Limitations"
            ]
            5 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1551034"
          "titulo" => "Keywords"
        ]
        2 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        3 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Methods"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Definitions"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Statistical analysis"
            ]
          ]
        ]
        4 => array:3 [
          "identificador" => "sec0025"
          "titulo" => "Results"
          "secciones" => array:5 [
            0 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "No significant differences between Oma-responders and Cs-A-responders but some features are more prevalent in Cs-A-responders"
            ]
            1 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Oma-responders have higher baseline UCT scores compared to Oma-non-responders"
            ]
            2 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "High CRP levels are more frequent in Cs-A-responders compared to Cs-A-non-responders"
            ]
            3 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Female gender and lower baseline UCT were more frequent in non-responders of either drug"
            ]
            4 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Responders to both drugs had less angioedema and higher baseline UCT"
            ]
          ]
        ]
        5 => array:2 [
          "identificador" => "sec0055"
          "titulo" => "Discussion"
        ]
        6 => array:2 [
          "identificador" => "sec0060"
          "titulo" => "Conclusion"
        ]
        7 => array:2 [
          "identificador" => "sec0065"
          "titulo" => "Funding sources"
        ]
        8 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Authors&#39; contributions"
        ]
        9 => array:2 [
          "identificador" => "sec0075"
          "titulo" => "Conflicts of interest"
        ]
        10 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2022-01-05"
    "fechaAceptado" => "2022-03-07"
    "PalabrasClave" => array:1 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1551034"
          "palabras" => array:4 [
            0 => "Biomarker"
            1 => "Chronic urticaria"
            2 => "Cyclosporine"
            3 => "Omalizumab"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:1 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Background</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Chronic Spontaneous Urticaria &#40;CSU&#41; is characterized by recurrent wheals and&#47;or angioedema for longer than 6-weeks&#46; Guidelines recommend Omalizumab &#40;Oma&#41; as first-line and Cyclosporine-A &#40;Cs-A&#41; as second-line treatment in antihistamine resistant CSU&#46; This step-wise algorithm might be time-consuming and costly&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Objective</span><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">To determine indicators of response to Oma or Cs-A in CSU patients&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Methods</span><p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">We retrospectively analyzed data from seven centers in Turkey&#59; the inclusion criteria for patients were to receive both Oma and Cs-A treatment &#40;not concurrently&#41; at some point in time during their follow-up&#46; Clinical and laboratory features were compared between groups&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Results</span><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Among 110 CSU patients&#59; 47 &#40;42&#46;7&#37;&#41; were Oma-responders&#44; 15 &#40;13&#46;6&#37;&#41; were Cs-A-responders&#44; and 24 &#40;21&#46;8&#37;&#41; were both Oma and Cs-A responders and 24 &#40;21&#46;8&#37;&#41; were non-responders to either drug&#46; High CRP levels were more frequent in Cs-A-responders &#40;72&#46;7&#37; vs&#46; 40&#46;3&#37;&#59; p &#61; 0&#46;055&#41;&#46; Oma-responders had higher baseline UCT &#40;Urticaria Control Test&#41; scores &#40;6 vs&#46; 4&#46;5&#59; p &#61; 0&#46;045&#41;&#46; Responders to both drugs had less angioedema and higher baseline UCT scores compared to other groups &#40;33&#46;3&#37; vs&#46; 62&#46;8&#37;&#59; p &#61; 0&#46;01 and 8 vs&#46; 5&#59; p &#61; 0&#46;017&#41;&#46; Non-responders to both drugs had an increased frequency in the female gender and lower baseline UCT scores compared to other groups &#40;87&#46;5&#37; vs&#46; 61&#46;6&#37;&#59; p &#61; 0&#46;017 and 5 vs&#46; 7&#59; p &#61; 0&#46;06&#41;&#46;</p></span> <span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Study Limitations</span><p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Retrospective nature&#44; limited number of patients&#44; no control group&#44; the lack of the basophil activation &#40;BAT&#41; or BHRA &#40;basophil histamine release assay&#41; tests&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Conclusions</span><p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Baseline disease activity assessment&#44; which considers the presence of angioedema and disease activity scores&#44; gender&#44; and CRP levels might be helpful to predict treatment outcomes in CSU patients and to choose the right treatment for each patient&#46; Categorizing patients into particular endotypes could provide treatment optimization and increase treatment success&#46;</p></span>"
        "secciones" => array:6 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Background"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Objective"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Methods"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Results"
          ]
          4 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Study Limitations"
          ]
          5 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Conclusions"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Study conducted at the Department of Dermatology&#44; Koc University&#44; School of Medicine&#44; Istanbul&#44; Turkey&#59; Department of Dermatology&#44; Uludag University&#44; School of Medicine&#44; Bursa&#44; Turkey&#59; Department of Dermatology&#44; Bezmialem Vakif University&#44; School of Medicine&#44; Istanbul&#44; Turkey&#59; Department of Dermatology&#44; Istanbul Medipol University&#44; School of Medicine&#44; Istanbul&#44; Turkey&#59; Department of Dermatology&#44; Ankara Diskapi Yildirim Beyazit Training and Research Hospital&#44; Ankara&#44; Turkey&#59; Department of Dermatology&#44; VM Medical Park Maltepe Hospital&#44; Istanbul&#44; Turkey&#59; Department of Dermatology&#44; Istanbul University&#44; Cerrahpasa School of Medicine&#44; Istanbul&#44; Turkey&#59; Department of Dermatology&#44; Hacettepe University&#44; School of Medicine&#44; Ankara&#44; Turkey&#59; Department of Dermatology&#44; Akdeniz University&#44; School of Medicine&#44; Antalya&#44; Turkey&#46;</p>"
      ]
    ]
    "multimedia" => array:5 [
      0 => array:8 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1672
            "Ancho" => 1675
            "Tamanyo" => 199167
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The distribution of four types of treatment responses&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0010"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">CINDU&#44; Chronic Inducible Urticaria&#59; UCT&#44; Urticaria Control Test&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Demographic and clinical parameters&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Total &#40;n &#61; 110&#44; &#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Oma responders &#40;n &#61; 47&#44; 42&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Cs-A responders &#40;n &#61; 15&#44; 13&#46;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Both Oma and Cs-A responders &#40;n &#61; 24&#44; 21&#46;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Non-responders &#40;n &#61; 24&#44; 21&#46;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Age in years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Min&#8210;Max &#40;Median&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16&#8210;81 &#40;39&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27&#8210;81 &#40;42&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16&#8210;73 &#40;37&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21&#8210;66 &#40;34&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20&#8210;69 &#40;37&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mean &#177; SD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#46;98 &#177; 12&#46;37&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">43&#46;32 &#177; 10&#46;67&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#46;20 &#177; 16&#46;52&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37&#46;79 &#177; 12&#46;18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#46;08 &#177; 12&#46;64&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Gender n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Male&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">36 &#40;32&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;38&#46;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;40&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;37&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;12&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Female&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">74 &#40;67&#46;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">29 &#40;61&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;60&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;62&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21 &#40;87&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">Accompanying CINDU n &#40;&#37;&#41;</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 99&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 24&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21 &#40;21&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;20&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;20&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;17&#46;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;25&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Disease duration &#40;months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Min&#8210;Max &#40;Median&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#8210;402 &#40;30&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8210;300 &#40;30&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#8210;120 &#40;36&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#8210;264 &#40;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#8210;402 &#40;36&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mean &#177; SD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">57&#46;21 &#177; 69&#46;31&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">60&#46;32 &#177; 71&#46;26&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">45&#46;53 &#177; 38&#46;33&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51&#46;46 &#177; 63&#46;72&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">64&#46;17 &#177; 86&#46;37&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Angioedema&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">62 &#40;56&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27 &#40;57&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;66&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;33&#46;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17 &#40;70&#46;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Baseline UCT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 83&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 41&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Min&#8210;Max &#40;Median&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#8210;16 &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#8210;16 &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8210;9 &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#8210;16 &#40;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#8210;11 &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mean &#177; SD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#177; 4&#46;34&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#46;44 &#177; 4&#46;65&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46;75 &#177; 3&#46;06&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9&#46;12 &#177; 3&#46;81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#46;11 &#177; 3&#46;53&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">UCT &#8805; 6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46 &#40;55&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23 &#40;56&#46;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;37&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;81&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;38&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">UCT &#60; 6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37 &#40;44&#46;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;43&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;62&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;18&#46;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;61&#46;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Positive family history n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;10&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;4&#46;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;20&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;12&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;12&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Demographic and clinical characteristics of the patients&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0015"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">anti-TG&#44; anti-Thyroglobulin antibody&#59; anti-TPO&#44; anti-Thyroid Peroxidase antibody&#59; CRP&#44; C-Reactive Protein&#59; ESR&#44; Erythrocyte Sedimentation Rate&#59; <span class="elsevierStyleItalic">H&#46; pylori</span>&#44; <span class="elsevierStyleItalic">Helicobacter pylori</span>&#59; ASST&#44; Autologous Serum Skin Test&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Laboratory finding&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Total &#40;n &#61; 110&#44; &#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Oma &#40;only&#41; responder &#40;n &#61; 47&#44; 42&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Cs-A &#40;only&#41; responder &#40;n &#61; 15&#44; 13&#46;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Both oma and Cs-A responder &#40;n &#61; 24&#44; 21&#46;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Non-responder &#40;n &#61; 24&#44; 21&#46;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">High levels of CRP</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 88&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 38&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">39 &#40;44&#46;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16 &#40;42&#46;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;72&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;33&#46;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;44&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">High levels of ESR</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 99&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 44&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">39 &#40;39&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;34&#46;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;61&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;42&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;33&#46;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">Eosinopenia</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 23&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;5&#46;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;20&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;8&#46;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">Basipodia</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 102&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 24&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;3&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;2&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;16&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">ASST positivity</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 77&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 36&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44 &#40;57&#46;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">19 &#40;52&#46;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;71&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;58&#46;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;58&#46;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">Serum total IgE levels &#40;IU&#47;mL&#41;</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;03&#8210;6350 &#40;167&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#44;28&#8210;6350 &#40;169&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;03&#8210;1282 &#40;280&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&#44;4 3&#8210;16 06 &#40;150&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9&#8210;1434 &#40;172&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">370&#46;65 &#177; 727&#46;22&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">476&#46;35 &#177; 1000&#46;81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">343&#46;27 &#177; 392&#46;27&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">252&#46;58 &#177; 368&#46;81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">271&#46;05 &#177; 328&#46;70&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">Serum total IgE levels lower than 43 &#40;IU&#47;mL&#41;</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 94&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23 &#40;24&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;20&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;41&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;16&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;28&#46;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">Autoimmune thyroid disease</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 35&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17 &#40;21&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;22&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;22&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;10&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;29&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">High levels of anti-TPO antibody n &#40;&#37;&#41;</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 72&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 29&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25 &#40;34&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;37&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;50&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;21&#46;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;37&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">High levels of anti-TG antibody n &#40;&#37;&#41;</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 66&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 25&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;27&#46;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;32&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;25&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;15&#46;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;35&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="middle">Positive H&#46;pylori antigen in stool n &#40;&#37;&#41;</td><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 87&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 41&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n &#61; 15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31 &#40;35&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;31&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;33&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;36&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;46&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Laboratory findings of the patients shown for each group&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0020"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">anti-TPO&#44; anti-Thyroid Peroxidase antibody&#59; anti-TG&#44; anti-Thyroglobulin antibody&#59; ASST&#44; Autologous Serum Skin Test&#59; CRP&#44; C-Reactive Protein&#59; Cs-A&#44; Cyclosporine-A&#59; ESR&#44; Erythrocyte Sedimentation Rate&#59; <span class="elsevierStyleItalic">H&#46;pylori</span>&#44; <span class="elsevierStyleItalic">Helicobacter pylori</span>&#59; Oma&#44; Omalizumab&#59; UCT&#44; Urticaria Control Test&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Treatment group&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">p &#60; 0&#46;05&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">p &#62; 0&#46;05&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oma &#40;only&#41; responders vs&#46; Cs-A &#40;only&#41; responders&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">More frequent in Cs-A responders&#58; Positive ASST&#44; positive family history&#44; high CRP&#44; basopenia&#44; eosinopenia&#44; high ESR&#44; low total IgE levels&#44; anti-TPO positivity&#44; lower baseline UCT scores&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oma responders vs&#46; oma-non-responders&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Higher in oma responders&#58; Baseline UCT score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">More frequent in Oma-responders&#58; Male gender&#44; lower rates of ASST positivity&#44; lower rates of family history&#44; lower frequency of high CRP&#44; lower frequency of eosinopenia&#44; lower frequency of basopenia&#44; lower frequency of high ESR levels&#44; lower frequency of angioedema&#44; lower frequency of autoimmune thyroid disease&#44; higher frequency of total IgE levels greater than 43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cs-A responders vs&#46; Cs-A-non-responders&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">More frequent in Cs-A responders&#58; High CRP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">More frequent in Cs-A responders&#58; Positive family history&#44; positive ASST&#44; eosinopenia&#44; basopenia&#44; high ESR levels&#44; lower total IgE levels&#44; anti-TPO positivity&#44; lower baseline UCT scores&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Responders to both drugs vs&#46; other three groups&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">More frequent in both drug responders&#58; Lower angioedema frequency&#44; higher baseline UCT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Less frequent in both drug responders&#58; High CRP&#44; eosinopenia&#44; basopenia&#44; autoimmune thyroid disease&#44; anti-TPO positivity&#44; anti-TG positivity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Non-responders to either drug vs&#46; other three groups&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Higher frequency in non-responders&#58; Female gender&#44; lower baseline UCT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Higher frequency in non-responders&#58; Angioedema&#44; autoimmune thyroid disease&#44; anti-TG positivity&#44; <span class="elsevierStyleItalic">H&#46;pylori</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cs-A responders vs&#46; Cs-A-non-responders&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">More frequent in Cs-A responders&#58; High CRP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">More frequent in Cs-A responders&#58; Positive family history&#44; positive ASST&#44; eosinopenia&#44; basopenia&#44; high ESR levels&#44; lower total IgE levels&#44; anti-TPO positivity&#44; lower baseline UCT scores&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Demonstration of statistically significant and statistically no-significant but more frequent features observed between the treatment response groups&#46;</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0025"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">anti-TPO&#44; anti-Thyroid Peroxidase antibody&#59; anti-TG&#44; anti-Thyroglobulin antibody&#59; ASST&#44; Autologous Serum Skin Test&#59; BAT&#44; Basophil Activation Test&#59; BHRA&#44; Basophil Histamine Release Assay&#59; CRP&#44; C-Reactive Protein&#59; Cs-A&#44; Cyclosporine-A&#59; CSU&#44; Chronic Spontaneous Urticaria&#59; ESR&#44; Erythrocyte Sedimentation Rate&#59; <span class="elsevierStyleItalic">H&#46;pylori&#44; Helicobacterpylori</span>&#59; Oma&#44; Omalizumab&#59; UCT&#44; Urticaria Control Test&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">What is already known about the topic&#63;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">What does this article add&#63;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Autoimmunity in CSU has been classified into type 1 autoimmune &#40;IgE type-autoallergic&#41; and type 2b autoimmune &#40;IgG type&#41; mechanisms&#46; These two types have been associated with different clinical and laboratory features and treatment response patterns&#46; Type 1 autoimmune urticaria is associated with IgE antibodies against autoantigens&#44; higher rates of concomitant allergic diseases&#44; normal or high total IgE levels and high response rates to omalizumab&#46; Type 2b autoimmune urticaria is associated with IgG antibodies against autoantigens&#44; BHRA&#44; BAT&#44; ASST positivity&#44; more severe disease with longer duration&#44; higher rates of concomitant autoimmune diseases&#44; higher rates of basopenia and eosinopenia&#44; lower total IgE levels&#44; higher CRP levels&#44; higher ANA positivity&#44; low response rates to antihistamines and omalizumab&#44; higher response rates to immunosuppressive therapy&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">We found two distinct patterns of CSU endotypes according to their treatment response patterns which are compatible with the two different autoimmune urticaria endotypes&#59; Oma responders tended to be more male gender with a lower disease activity &#40;higher baseline UCT scores&#41; and with lower rates of ASST positivity&#44; lower rates of family history&#44; lower CRP levels&#44; lower rates of basopenia and eosinopenia&#44; lower ESR levels&#44; lower frequency of angioedema&#44; lower frequency of autoimmune thyroid disease and higher total IgE levels&#46; These are features that have been linked to type 1 &#40;IgE type&#41; autoimmunity&#46; Cs-A responders had higher CRP levels and higher frequency of positive family history&#44; positive ASST&#44; eosinopenia&#44; basopenia&#44; higher ESR levels&#44; higher frequency of anti-TPO positivity&#44; lower total IgE levels and higher disease activity &#40;lower baseline UCT scores&#41;&#46; These are features that have been linked to type 2b &#40;IgG type&#41; autoimmunity&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Biomarkers for Oma response has been reported to be high levels of total IgE&#44; ASST negativity&#44; BHRA negativity&#44; lack of basophil CD203c-upregulating activity&#44; high expression of basophil Fc&#949;RI and lower IL-31 levels while biomarkers for cyclosporine response has been reported to be BHRA positivity&#44; higher CRP levels&#44; low total IgE levels&#44; ASST positivity&#44; low D-dimer levels&#44; high disease activity and short disease duration&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Non-responders to either drugs are more female with higher disease activity and with more angioedema&#44; autoimmune thyroid disease&#44; thyroid autoantibodies and <span class="elsevierStyleItalic">H&#46;pylori</span> positivity&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">What is already known about the topic&#44; what does this article add&#63;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:29 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The EAACI&#47;GA&#40;2&#41;LEN&#47;EDF&#47;WAO guideline for the definition&#44; classification&#44; diagnosis and management of urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Zuberbier"
                            1 => "W&#46; Aberer"
                            2 => "R&#46; Asero"
                            3 => "A&#46;H&#46; Abdul Latiff"
                            4 => "D&#46; Baker"
                            5 => "B&#46; Ballmer-Weber"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/all.13397"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy&#46;"
                        "fecha" => "2018"
                        "volumen" => "73"
                        "paginaInicial" => "1393"
                        "paginaFinal" => "1414"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29336054"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Looking forward to new targeted treatments for chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46; Kocaturk"
                            1 => "M&#46; Maurer"
                            2 => "M&#46; Metz"
                            3 => "C&#46; Grattan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s13601-016-0139-2"
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Transl Allergy&#46;"
                        "fecha" => "2017"
                        "volumen" => "7"
                        "paginaInicial" => "1"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28078079"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Urticaria&#58; Collegium Internationale Allergologicum &#40;CIA&#41; Update 2020"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Maurer"
                            1 => "K&#46; Eyerich"
                            2 => "S&#46; Eyerich"
                            3 => "M&#46; Ferrer"
                            4 => "J&#46; Gutermuth"
                            5 => "K&#46; Hartmann"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000507218"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int Arch Allergy Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "181"
                        "paginaInicial" => "321"
                        "paginaFinal" => "333"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32224621"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutting Edge&#58; Biomarkers for Chronic Spontaneous Urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "M&#46; Folci"
                            1 => "E&#46; Heffler"
                            2 => "G&#46;W&#46; Canonica"
                            3 => "R&#46; Furlan"
                            4 => "E&#46; Brunetta"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1155/2018/9464186"
                      "Revista" => array:4 [
                        "tituloSerie" => "J Immunol Res&#46;"
                        "fecha" => "2018"
                        "volumen" => "2018"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29854852"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "L&#46; Santiago"
                            1 => "B&#46; Ferreira"
                            2 => "L&#46; Ramos"
                            3 => "M&#46; Goncalo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.17005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "180"
                        "paginaInicial" => "199"
                        "paginaFinal" => "200"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30007073"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Factors Predicting the Response to Cyclosporin Treatment in Patients With Chronic Spontaneous Urticaria&#58; A Systematic Review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "K&#46; Kulthanan"
                            1 => "C&#46; Subchookul"
                            2 => "S&#46; Hunnangkul"
                            3 => "L&#46; Chularojanamontri"
                            4 => "P&#46; Tuchinda"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4168/aair.2019.11.5.736"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy Asthma Immunol Res&#46;"
                        "fecha" => "2019"
                        "volumen" => "11"
                        "paginaInicial" => "736"
                        "paginaFinal" => "755"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31332983"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Potential blood biomarkers in chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "P&#46; Kolkhir"
                            1 => "F&#46; Andre"
                            2 => "M&#46;K&#46; Church"
                            3 => "M&#46; Maurer"
                            4 => "M&#46; Metz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/cea.12870"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Allergy"
                        "fecha" => "2017"
                        "volumen" => "47"
                        "paginaInicial" => "19"
                        "paginaFinal" => "36"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27926978"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria&#58; Results of the PURIST Study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "N&#46; Schoepke"
                            1 => "R&#46; Asero"
                            2 => "A&#46; Ellrich"
                            3 => "M&#46; Ferrer"
                            4 => "A&#46; Gimenez-Arnau"
                            5 => "C&#46;E&#46;H&#46; Grattan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/all.13949"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy&#46;"
                        "fecha" => "2019"
                        "volumen" => "74"
                        "paginaInicial" => "2427"
                        "paginaFinal" => "2436"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31228881"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Randomized double-blind study of cyclosporin in chronic&#8217; idiopathic&#8217; urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;E&#46; Grattan"
                            1 => "B&#46;F&#46; O&#8217;Donnell"
                            2 => "D&#46;M&#46; Francis"
                            3 => "N&#46; Niimi"
                            4 => "R&#46;J&#46; Barlow"
                            5 => "P&#46;T&#46; Seed"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1046/j.1365-2133.2000.03664.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2000"
                        "volumen" => "143"
                        "paginaInicial" => "365"
                        "paginaFinal" => "372"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10951147"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A positive serum basophil histamine release assay is a marker for ciclosporin-responsiveness in patients with chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "K&#46; Iqbal"
                            1 => "K&#46; Bhargava"
                            2 => "P&#46;S&#46; Skov"
                            3 => "S&#46; Falkencrone"
                            4 => "C&#46;E&#46; Grattan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/2045-7022-2-19"
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Transl Allergy&#46;"
                        "fecha" => "2012"
                        "volumen" => "2"
                        "paginaInicial" => "19"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23025508"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Factors that predict the success of cyclosporine treatment for chronic urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "S&#46;M&#46; Hollander"
                            1 => "S&#46;S&#46; Joo"
                            2 => "H&#46;J&#46; Wedner"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.anai.2011.08.013"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Allergy Asthma Immunol&#46;"
                        "fecha" => "2011"
                        "volumen" => "107"
                        "paginaInicial" => "523"
                        "paginaFinal" => "528"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22123382"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Response to oral cyclosporine therapy and high sensitivity-CRP level in chronic idiopathic urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "T&#46; Ohtsuka"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-4632.2010.04384.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Dermatol&#46;"
                        "fecha" => "2010"
                        "volumen" => "49"
                        "paginaInicial" => "579"
                        "paginaFinal" => "584"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20534097"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria&#58; Real-life data"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46; Salman"
                            1 => "G&#46; Demir"
                            2 => "N&#46; Bekiroglu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Dermatol Ther"
                        "fecha" => "2019"
                        "volumen" => "32"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "R&#46; Ertas"
                            1 => "K&#46; Ozyurt"
                            2 => "M&#46; Atasoy"
                            3 => "T&#46; Hawro"
                            4 => "M&#46; Maurer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/all.13345"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy"
                        "fecha" => "2018"
                        "volumen" => "73"
                        "paginaInicial" => "705"
                        "paginaFinal" => "712"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29083482"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;D&#46; Straesser"
                            1 => "E&#46; Oliver"
                            2 => "T&#46; Palacios"
                            3 => "T&#46; Kyin"
                            4 => "J&#46; Patrie"
                            5 => "L&#46; Borish"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2017.10.030"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2018"
                        "volumen" => "6"
                        "paginaInicial" => "1386"
                        "paginaFinal" => "1388"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29175369"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Factors related to omalizumab resistance in chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46; Magen"
                            1 => "T&#46; Chikovani"
                            2 => "D&#46;A&#46; Waitman"
                            3 => "N&#46;R&#46; Kahan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2500/aap.2019.40.4230"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy Asthma Proc&#46;"
                        "fecha" => "2019"
                        "volumen" => "40"
                        "paginaInicial" => "273"
                        "paginaFinal" => "278"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31262381"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Basophil FcepsilonRI Expression in Chronic Spontaneous Urticaria&#58; A Potential Immunological Predictor of Response to Omalizumab Therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Deza"
                            1 => "M&#46; Bertolin-Colilla"
                            2 => "R&#46;M&#46; Pujol"
                            3 => "L&#46; Curto-Barredo"
                            4 => "D&#46; Soto"
                            5 => "M&#46; Garcia"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2340/00015555-2654"
                      "Revista" => array:6 [
                        "tituloSerie" => "Acta Derm Venereol&#46;"
                        "fecha" => "2017"
                        "volumen" => "97"
                        "paginaInicial" => "698"
                        "paginaFinal" => "704"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28303277"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Eosinopenia&#44; in Chronic Spontaneous Urticaria&#44; Is Associated with High Disease Activity&#44; Autoimmunity&#44; and Poor Response to Treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Kolkhir"
                            1 => "M&#46;K&#46; Church"
                            2 => "S&#46; Altrichter"
                            3 => "P&#46;S&#46; Skov"
                            4 => "T&#46; Hawro"
                            5 => "S&#46; Frischbutter"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2019.08.025"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2020"
                        "volumen" => "8"
                        "paginaInicial" => "318"
                        "paginaFinal" => "325"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31472293"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cyclosporine and omalizumab together&#58; A new option for chronic refractory urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46; Sanchez"
                            1 => "L&#46; Alvarez"
                            2 => "R&#46; Cardona"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2020.02.012"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2020"
                        "volumen" => "8"
                        "paginaInicial" => "2101"
                        "paginaFinal" => "2103"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32112923"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Concomitant treatment with omalizumab and cyclosporine for chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "J&#46;D&#46; Rosenblum"
                            1 => "S&#46; Nassau"
                            2 => "L&#46; Fonacier"
                            3 => "S&#46;L&#46; Mawhirt"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.anai.2020.04.020"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Allergy Asthma&#46; Immunol"
                        "fecha" => "2020"
                        "volumen" => "125"
                        "paginaInicial" => "111"
                        "paginaFinal" => "112"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32360694"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Combination therapy with omalizumab and an immune-suppressive agent for resistant chronic spontaneous rrticaria - A real-life experience"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "R&#46; Maoz-Segal"
                            1 => "T&#46; Levy"
                            2 => "S&#46; Haj-Yahia"
                            3 => "I&#46; Offengenden"
                            4 => "M&#46; Iancovich-Kidon"
                            5 => "N&#46; Agmon-Levin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.waojou.2020.100439"
                      "Revista" => array:4 [
                        "tituloSerie" => "World Allergy Organ J&#46;"
                        "fecha" => "2020"
                        "volumen" => "13"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32670463"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "R&#46; Asero"
                            1 => "A&#46;V&#46; Marzano"
                            2 => "S&#46; Ferrucci"
                            3 => "M&#46; Lorini"
                            4 => "V&#46; Carbonelli"
                            5 => "M&#46; Cugno"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/cei.13428"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Exp Immunol"
                        "fecha" => "2020"
                        "volumen" => "200"
                        "numero" => "3"
                        "paginaInicial" => "242"
                        "paginaFinal" => "249"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32115683"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Etiologic aspects and prognostic factors of patients with chronic urticaria&#58; nonrandomized&#44; prospective&#44; descriptive study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Gregoriou"
                            1 => "D&#46; Rigopoulos"
                            2 => "A&#46; Katsambas"
                            3 => "A&#46; Katsarou"
                            4 => "D&#46; Papaioannou"
                            5 => "A&#46; Gkouvi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2310/7750.2008.08035"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Cutan Med Surg"
                        "fecha" => "2009"
                        "volumen" => "13"
                        "numero" => "4"
                        "paginaInicial" => "198"
                        "paginaFinal" => "203"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19706227"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "&#91;Epidemiologic features in patients with antihistamine-resistant chronic urticaria&#93;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46;S&#46; Borges"
                            1 => "S&#46; Tassinari"
                            2 => "A&#46; Flores"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Alerg Mex&#46;"
                        "fecha" => "2015"
                        "volumen" => "62"
                        "paginaInicial" => "279"
                        "paginaFinal" => "286"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26556663"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Grieco"
                            1 => "L&#46; Dies"
                            2 => "A&#46; Sernicola"
                            3 => "C&#46; Chello"
                            4 => "N&#46; Gagliostro"
                            5 => "G&#46; Carnicelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2217/imt-2020-0088"
                      "Revista" => array:6 [
                        "tituloSerie" => "Immunotherapy&#46;"
                        "fecha" => "2020"
                        "volumen" => "12"
                        "paginaInicial" => "1173"
                        "paginaFinal" => "1181"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32892673"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Omalizumab Updosing for Better Disease Control in Chronic Spontaneous Urticaria Patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46; Kocaturk"
                            1 => "G&#46; Deza"
                            2 => "K&#46; Kiziltac"
                            3 => "A&#46;M&#46; Gimenez-Arnau"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000491530"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int Arch Allergy Immunol&#46;"
                        "fecha" => "2018"
                        "volumen" => "177"
                        "paginaInicial" => "360"
                        "paginaFinal" => "364"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30130798"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Urticaria and Angioedema Across the Ages"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46; Saini"
                            1 => "M&#46; Shams"
                            2 => "J&#46;A&#46; Bernstein"
                            3 => "M&#46; Maurer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2020.03.030"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2020"
                        "volumen" => "8"
                        "paginaInicial" => "1866"
                        "paginaFinal" => "1874"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32298850"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biomarkers In Chronic Spontaneous Urticaria&#58; Current Targets And Clinical Implications"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "I&#46; Puxeddu"
                            1 => "F&#46; Petrelli"
                            2 => "F&#46; Angelotti"
                            3 => "C&#46; Croia"
                            4 => "P&#46; Migliorini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/JAA.S184986"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Asthma Allergy&#46;"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "paginaInicial" => "285"
                        "paginaFinal" => "295"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31571935"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "New treatments for chronic urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "P&#46; Kolkhir"
                            1 => "S&#46; Altrichter"
                            2 => "M&#46; Munoz"
                            3 => "T&#46; Hawro"
                            4 => "M&#46; Maurer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.anai.2019.08.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Allergy Asthma Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "124"
                        "paginaInicial" => "2"
                        "paginaFinal" => "12"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31446134"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/03650596/0000009700000005/v1_202208290604/S0365059622001386/v1_202208290604/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "89516"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Original Article"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/03650596/0000009700000005/v1_202208290604/S0365059622001386/v1_202208290604/en/main.pdf?idApp=UINPBA00008Z&text.app=https://clinics.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059622001386?idApp=UINPBA00008Z"
]